MMedXYNews
Ask AIHomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY News/Hematology-Oncology

Section

Hematology-Oncology

578 articles

Ask AI
All specialtiesHematology-OncologynewsClinical UpdatesCardiologyOncology

Latest updates

Hematology-Oncology

Noncanonical FLT3-ITD Signaling Drives Immune Evasion via PKCι-STAT1–Mediated CD8+ T-Cell Exhaustion in Acute Myeloid Leukemia

FLT3-ITD mutations in AML promote immune evasion through a novel PKCι–STAT1 signaling axis that induces CD276-mediated CD8+ T-cell exhaustion, offering a promising target for combined FLT3 and CD276-directed therapies.

Jul 15, 2026Sign in to read
Hematology-Oncology

Early Software-Assisted Evaluation Enhances Prediction of Survival in Newly Diagnosed Chronic Graft-versus-Host Disease Patients

Software-assisted response evaluation at six months reliably predicts survival outcomes in chronic graft-versus-host disease, offering a promising tool to guide treatment decisions and improve patient prognosis.

Jul 13, 2026
Hematology-Oncology

Pavurutamab, a BCMA-Targeting Bispecific T-Cell Engager: Promising Phase 1/1b Results in Triple-Class Relapsed/Refractory Multiple Myeloma

Pavurutamab demonstrates manageable safety and encouraging efficacy in heavily pretreated relapsed/refractory multiple myeloma, showing an overall response rate of 46.5% and median progression-free survival of 16.8 months at the recommended

Jul 13, 2026
Hematology-Oncology

Fludarabine with Treosulfan vs. Total Body Irradiation as Conditioning in ALL Transplantation: A Comparative Retrospective Analysis

This retrospective matched-pair study compares fludarabine combined with treosulfan or total body irradiation as conditioning regimens before allogeneic stem cell transplantation in adult acute lymphoblastic leukemia, finding no significant

Jul 12, 2026Sign in to read
Hematology-Oncology

Unraveling Genetic Drivers in Triple Negative Thrombocytosis: Implications of MPL and SH2B3/LNK Mutations

Comprehensive genetic screening of triple negative thrombocytosis reveals germline MPL compound mutations and truncating SH2B3/LNK alterations, offering new insights into diagnosis and personalized management.

Jul 12, 2026Sign in to read
Superintelligence

MAIPI: A Novel AI-Powered Prognostic Index for Mantle Cell Lymphoma Using Routine Histology

The MAIPI deep learning model offers a novel, accurate prognosis tool for mantle cell lymphoma, using standard H&E stained biopsy images, bypassing need for molecular tests or expert pathology, and enhancing risk stratification for indi

Jul 12, 2026Sign in to read
Hematology-Oncology

Decoding PIEZO1 Variants: Precision Insights into Hereditary Red Blood Cell and Iron Disorders

This study refines the classification of PIEZO1 variants using integrative genomic and phenotypic data, enhancing diagnosis and personalized management of hereditary red blood cell and iron disorders like dehydrated hereditary stomatocytosi

Jul 12, 2026
Hematology-Oncology

Synergistic Impact of Clonal Hematopoiesis and Genetic Predisposition on Age-Related Macular Degeneration Risk: Insights from a Large UK Biobank Cohort

This cohort study reveals that clonal hematopoiesis of indeterminate potential (CHIP) independently increases age-related macular degeneration (AMD) risk, with amplified effects when combined with high genetic susceptibility, especially in

Jul 11, 2026Sign in to read
Hematology-Oncology

CHIME: A Novel HLA Eplet Model Predicting Non-Relapse Mortality in Haploidentical Hematopoietic Cell Transplantation

This study introduces CHIME, a novel HLA eplet mismatch model, revealing its association with non-relapse mortality and severe aGvHD in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide, improving

Jul 9, 2026
Clinical Updates

Long-term Outcomes of Oral Decitabine/Cedazuridine Plus Venetoclax in Older or Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Oral decitabine/cedazuridine plus venetoclax provides an effective, fully oral frontline therapy for older or unfit patients with AML, showing encouraging response rates and manageable safety with long-term follow-up, highlighting particula

Jul 9, 2026
Hematology-Oncology

Decoding Resistance to Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm: The Role of TXNRD1 and TET2 Mutations

This article explores how decreased TXNRD1 expression and specific TET2 mutations are linked to tagraxofusp resistance in BPDCN patients, highlighting biomarkers that could guide future therapeutic strategies.

Jul 9, 2026
Hematology-Oncology

Unveiling Non-PF4/Heparin-Binding, Platelet-Activating Antibodies in Heparin-Induced Thrombocytopenia: Implications for Diagnosis and Pathogenesis

Recent findings identify a prevalent subset of platelet-activating antibodies in HIT that evade traditional PF4/heparin ELISA detection, highlighting new diagnostic and pathogenic insights.

Jul 9, 2026
Hematology-Oncology

Evaluating the ISOLD Score for Accurate Diagnosis of Vitreoretinal Lymphoma in Clinical Practice

This study validates the ISOLD score, a cytokine-based probabilistic tool, demonstrating high sensitivity and specificity for diagnosing vitreoretinal lymphoma from aqueous humor samples, outperforming standard IL-10/IL-6 ratios, with impli

Jul 9, 2026Sign in to read
Critical Care

Harnessing Machine Learning for Prognostic Precision in Secondary Hemophagocytic Lymphohistiocytosis

The HLH-Risk-Calculator utilizes machine learning to predict initial disease severity and mortality at multiple time points in adult patients with secondary hemophagocytic lymphohistiocytosis, highlighting key biomarkers and advocating for

Jul 7, 2026
Hematology-Oncology

A Comprehensive Prognostic Model for Predicting Leukemia-Free Survival Following Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia

This article discusses a novel holistic H-score prognostic model integrating patient, disease, and treatment factors to predict leukemia-free survival after allogeneic transplantation in acute leukemia, enhancing risk stratification beyond

Jul 7, 2026
Hematology-Oncology

Recurrent Venous Thromboembolism After Isolated Distal DVT: Insights from the RIDTS Trial

This article reviews the incidence and predictors of recurrent VTE following anticoagulation for isolated distal deep vein thrombosis, highlighting key risk factors and implications for treatment duration and patient management.

Jul 7, 2026
Hematology-Oncology

Linperlisib Potentiates MUC1-Tn CAR T Cell Therapy by Suppressing the EGR1/DUSP2 Axis to Combat T-Cell Acute Lymphoblastic Leukemia

This study highlights how linperlisib, a PI3Kδ inhibitor, enhances MUC1-Tn CAR T cell efficacy in T-ALL by preventing T cell exhaustion via suppression of the EGR1/DUSP2 pathway, improving anti-leukemic activity and persistence.

Jul 6, 2026Sign in to read
Hematology-Oncology

Engineering Single-Chain Variable Fragments to Identify Pathogenic Antibodies in Heparin-Induced Thrombocytopenia

Development of engineered antibody fragments enables precise detection of pathogenic antibodies in heparin-induced thrombocytopenia, improving diagnosis and understanding of this immune-mediated blood disorder.

Jul 6, 2026Sign in to read
Hematology-Oncology

PASS: A Simplified Clinical Tool to Differentiate Acquired Aplastic Anemia from Inherited Bone Marrow Failure Syndromes in Adults

The Predictive Aplastic Score System (PASS) accurately distinguishes acquired aplastic anemia from inherited bone marrow failure syndromes using seven clinical variables, enabling rapid diagnosis and improved treatment decisions in adults.

Jul 4, 2026Sign in to read
Hematology-Oncology

Decoding Clonal Evolution and Immunophenotype in NPM1-Mutated AML through Single-Cell Multiomics

Single-cell multiomic analysis reveals how genotype-immunophenotype relationships shape clonal evolution in NPM1-mutated acute myeloid leukemia, highlighting implications for prognosis and therapy response.

Jul 2, 2026
Previous
13 / 25
1…1112131415…25
Next

Most read

  1. 01Hematology-Oncology

    Precision Immunotherapy in Acute Myeloid Leukemia: Advancing Beyond Traditional Targets

  2. 02Hematology-Oncology

    Targeting MERTK in CLL: A Promising Strategy for Overcoming Ibrutinib Resistance

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.